natgillin/translations-raw huggingface dataset:
28 hard capsules: EU/1/09/525/020 30 hard capsules: EU/1/09/525/021 56 hard capsules: EU/1/09/525/022 60 hard capsules: EU/1/09/525/023 112 hard capsules: EU/1/09/525/024 200 hard capsules: EU/1/09/525/050 250 hard capsules: EU/1/09/525/025
28 trdih kapsul: EU/1/09/525/020 30 trdih kapsul: EU/1/09/525/021 56 trdih kapsul: EU/1/09/525/022 60 trdih kapsul: EU/1/09/525/023 112 trdih kapsul: EU/1/09/525/024 200 trdih kapsul: EU/1/09/525/050 250 trdih kapsul: EU/1/09/525/025
28 hard gastro-resistant capsules 7 hard gastro-resistant capsules
28 trdih gastrorezistentnih kapsul 7 trdih gastrorezistentnih kapsul
28 hard gastro-resistant capsules 7 hard gastro-resistant capsules 98 hard gastro-resistant capsules
28 trdih gastrorezistentnih kapsul 7 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
28 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
28 July 2009
28. julij 2009
28 kg to < 35 kg who are able to swallow film-coated tablets is one 204 mg tablet once daily taken orally with food.
28 kg do < 35 kg, ki lahko pogoltnejo filmsko obložene tablete, je ena 204 mg tableta enkrat dnevno, peroralno, s hrano.
28 mcg/day
28 mcg/dan
28 mcg/day via continuous infusion
28 mcg/dan v kontinuirani infuziji
28 mg (0.3 ml) twice daily
28 mg (0,3 ml) dvakrat na dan
28 mg (0.3 ml) twice daily
28 mg (0.3 ml) dvakrat na dan
28 mg per kilogram body weight for patients receiving regular blood transfusions,
28 mg na kilogram telesne mase za bolnike, ki prejemajo redne transfuzije krvi,
28 out of 40 (70%) subjects achieved SVR12: 22/33 (73%) with HCV genotype 1 infection, 6/6 (100%) with HCV genotype 3 infection, and 0/1 (0%) with HCV genotype 4 infection.
28 od 40 (70 %) oseb je doseglo SVR12: 22/33 (73 %) oseb z okužbo s HCV genotipa 1, 6/6 (100 %) z okužbo s HCV genotipa 3 in 0/1 (0 %) z okužbo s HCV genotipa 4.
28 patches
28 transdermalnih obližev
28 patches (7x 2mg/24h, 7x 4mg/24h, 7x 6mg/24h, 7x 8mg/24h)
28 transdermalnih obližev (7x 2mg/24h, 7x 4mg/24h, 7x 6mg/24h, 7x 8mg/24h)
28 pre-filled syringes with solvent
28 napolnjenih injekcijskih brizg z vehiklom,
28 prolonged-release tablets (2 blisters of 14 tablets each) 56 prolonged-release tablets (4 blisters of 14 tablets each)
28 tablet s podaljšanim sproščanjem (2 pretisna omota po 14 tablet) 56 tablet s podaljšanim sproščanjem (4 pretisna omota po 14 tablet)
28 prolonged-release tablets (2 bottles of 14 tablets each) 56 prolonged-release tablets (4 bottles of 14 tablets each)
28 tablet s podaljšanim sproščanjem (2 plastenki po 14 tablet) 56 tablet s podaljšanim sproščanjem (4 plastenke po 14 tablet)
28 tablet box, 84 tablet box
škatla z 28 tabletami, škatla s 84 tabletami
28 tablets
(alu/alu)
28 tablets
(PVC/PVDC/Alu)
28 tablets
28 filmsko obloženih tablet
28 tablets
28 tableti
28 tablets
28 x 1 tablete
28 tablets
56 tablet
28 tablets
98 tablete
28 tablets
tablete (PP)
28 tablets (24 active + 4 placebo)
28 tablet (24 z zdravilnima učinkovinama + 4 placebo)
28 tablets (7 x 5
28 tablet (7 x 5 mg +
28 tablets (PA/Alu/PVC blisters)
28 tablet (PA/Alu/PVC pretisni omoti)
28 tablets (PVC/PCTFE blisters)
28 tablet (PVC/PCTFE pretisni omoti)
28 tablets: EU/1/08/480/002
28 tablet: EU/1/08/480/002
28 tablets: EU/1/10/632/002
28 tablet: EU/1/10/632/002
28 tablets: EU/1/10/632/009
28 tablet: EU/1/10/632/009
28 tablets: EU/1/10/632/016
28 tablet: EU/1/10/632/016
28 tablets: EU/1/11/721/002
28 tablet: EU/1/11/721/002
28 tablets: EU/1/11/721/009
28 tablet: EU/1/11/721/009
28 tablets: EU/1/11/721/016
28 tablet: EU/1/11/721/016
28 tablets: EU/1/11/723/002
28 tablet: EU/1/11/723/002
28 tablets: EU/1/11/723/009
28 tablet: EU/1/11/723/009
28 tablets: EU/1/11/723/016
28 tablet: EU/1/11/723/016
28 vials +
28 vial +
28 vials with 5 mg teduglutide as a powder
28 vial s po 5 mg teduglutida v obliki praška,
28 weeks
Krvni tlak
28 x 1 film-coated tablet
28 x 1 filmsko obložena tableta
28 x 1 film-coated tablets
28 x 1 filmsko obložena tableta
28 x 1 orodispersible tablet
28 x 1 orodisperzibilna tableta
28 x 1 orodispersible tablet:EU/1/09/525/027
28 x 1 orodisperzibilna tableta: EU/1/09/525/027
28 x 1 orodispersible tablet:EU/1/09/525/032
28 x 1 orodisperzibilna tableta: EU/1/09/525/032
28 x 1 orodispersible tablet:EU/1/09/525/037
28 x 1 orodisperzibilna tableta: EU/1/09/525/037
28 x 1 orodispersible tablet:EU/1/09/525/042
28 x 1 orodisperzibilna tableta: EU/1/09/525/042
28 x 1 orodispersible tablets
28 x 1 orodisperzibilna tableta
28 x 1 orodispersible tablets x 1 orodispersible tablets
28 x 1 orodisperzibilna tableta x 1 orodisperzibilna tableta
28 x 1 tablet (unit
28 x 1 tableta (enkratno
28 x 1 tablet (unit
30 x 1 tableta (enkratno
28 x 1 tablet (unit
60 x 1 tableta (enkratno
28 x 1 tablet (unit dose)
28 x 1 tableta (enkratni odmerek)
28 x 1 tablet (unit dose)
28 x 1 tableta (enkratno odmerjanje)
28 x 1 tablet (unit dose)
28 x 1 tableta (enoodmerno pakiranje)
28 x 1 tablet (unit dose)
28 x 1 tableta (za enkratni odmerek)
28 x 1 tablets
28 x 1 tablet
28 x 1 tablets
28 x 1 tablete
28 x 1 tablets (unit
(večkratno pakiranje)
28 x 1 tablets (unit dose)
28 x 1 tableta (enkratni odmerek)
28 x 1 tablets (unit dose)
28 x 1 tableta (enoodmerni pretisni omoti)
28 x 1 tablets (unit dose)
28 x 1 tableta (za
28 x 1 tablets (unit dose)
28 x 1 tableta (za enkratni odmerek)
28 x 1, 30 x 1, 56 x 1, 60 x 1 or 112 x 1 tablet in OPA/Alu/PVC foil film and PET/Alu peel off foil perforated unit dose blister packs in a box.
28 x 1, 30 x 1, 56 x 1, 60 x 1 ali 112 x 1 tableta v perforiranem enoodmernem pretisnem omotu iz OPA/Al/PVC-folije in PET/Al folije, ki se odlepi, v škatli.
28 x 10 capsules + 2 inhaler
28 x 10 kapsul + 2 inhalatorja
28 µg
18 µg
28, 56 or 112 capsules in transparent PVC/Alu push through blisters
28, 50, 56 ali 112 kapsul v prosojnem pretisnem omotu iz PVC/Alu.
28, hard gastro-resistant capsules 98, hard gastro-resistant capsules.
28 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
28-day course of Cayston was followed by a 28-day off drug period.
Vsakemu 28-dnevnemu ciklu zdravljenja je sledilo 28-dnevno obdobje brez jemanja zdravila.
28-Day Cycles 1 & 2
1. in 2. cikel 28-dnevnega cikla
28-Day Cycles 3+
3. in nadaljnji cikli 28-dnevnega cikla
28-day pack of Cayston
28-dnevni paket zdravila Cayston
28.0% (13.3, 42.6) p=0.0004
28,0 % (13,3; 42,6)
28.1 ng/ml; Ctrough = 91.6 ± 14.1 ng/ml; AUC0-24 = 2960 ± 268 ng.h/ml).
Cdno = 91,6 ± 14,1 ng/ml; AUC0–24 = 2960 ± 268 ng.h/ml).
28.3 mg/tablet
28,3 mg/tableto
28.6% (study MN301), and 49.4% vs.
49,4 % proti 26,3 % (študija US301).
28.9-37.1 months) for the VELCADE plus pegylated liposomal doxorubicin combination therapy patients.
VELCADE v kombinaciji s pegiliranim liposomskim doksorubicinom pa 33,0 mesecev (95% IZ; 28,9-37,1 meseca).
280 (20 x 14)
280 (20 x 14) tablet
280 (20 x 14) tablets (multipack)
280 (20 x 14) tablet (skupno pakiranje)
280 (20x14) tablets
280 (20x14) tablet
280 (20x14) tablets (multipack)
280 (20x14) tablet (skupno pakiranje)
280 tablets
280 tablet
280 tablets (20 x 14)
280 tablet (20 x 14)
280 tablets (20x14, PA/Alu/PVC blisters)
280 tablet (20x14, PA/Alu/PVC pretisni omoti)
280 tablets (20x14, PVC/PCTFE blisters)
280 tablet (20x14, PVC/PCTFE pretisni omoti)
280 tablets (4 x 70)
280 tablet (4 x 70)
280 tablets (multipack)
280 tablet (skupno pakiranje)
280 x 1 (4 x 70)
280 x 1 (4 x 70) tableta (skupno pakiranje)
280 x 1 tablet (unit dose)
280 x 1 tableta (za enkratni odmerek)
280 x 1 tablets (unit dose)
280 x 1 tableta (za enkratni odmerek)
2800 IU
2800 i.e.
28108 Madrid Spain
28108 Madrid Španija
28760 Madrid (SPAIN)
28760 Madrid (ŠPANIJA)
28760 Madrid SPAIN
28760 Madrid ŠPANIJA
28770 Colmenar Viejo (Madrid) Spain
28770 Colmenar Viejo (Madrid) Španija
288 h
288 ur
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - France
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - Francija
288n
288 n
28x1 film-coated tablets
28x1 filmsko obložena tableta
28x1 tablets
28x1 tableta
28x1 tablets (unit dose)
28 x 1 tableta (odmerek)
29 % of patients in 14 % of courses.
29 % bolnikov v 14 % ciklusov.
29 Avenue Tony Garnier 69007 Lyon
29 avenue Tony Garnier
29 avenue Tony Garnier F-69007 Lyon
29 avenue Tony Garnier 69007 Lyon
29 avenue Tony Garnier F-69007 LYON FRANCE
29 avenue Tony Garnier 69007 LYON FRANCIJA
29 avenue Tony Garnier F-69007 LYON FRANCE
29 avenue Tony Garnier F-69007 LYON FRANCIJA
29 route des Industries 37530 Pocé-sur-Cisse France
29 route des Industries 37530 Pocé-sur-Cisse Francija
29 units selected
29 enot
29% had locally advanced prostate cancer
29 % lokalno napredovalega raka prostate,
29% of patients treated with LEMTRADA reached SRD in study 2, while only 13% of subcutaneous IFNB- 1a treated patiets reached this endpoint.
V študiji 2 je SRD doseglo 29 % bolnikov, zdravljenih zdravilom LEMTRADA, in samo 13 % bolnikov, zdravljenih s subkutanim IFNB-1a.
29, avenue Tony Garnier 69007 Lyon
29 Avenue Tony Garnier 69007 Lyon
29, avenue Tony Garnier F-69007 Lyon
29 avenue Tony Garnier 69007 Lyon
29.3% a
29,3 %a
29.7 days (range, 9.9 to 91.2 days).The analysis data set contained 6003 quantifiable samples from 403 patients administered SC and/or IV rituximab in trials BP22333 (3736 samples from 277 patients) and BO22334 (2267 samples from126 patients).
Nabor podatkov za analizo je obsegal 6003 za kvantifikacijo primerne vzorce 403 bolnikov, ki so rituksimab dobili podkožno in/ali intravensko v preskušanjih BP22333 (3736 vzorcev 277 bolnikov) in BO22334 (2267 vzorcev 126 bolnikov).
29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p<0.0001).
Čas do napredovanja bolezni je bil v skupini, ki je jemala kapecitabin in docetaksel, daljši (p < 0,0001).
29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p < 0.0001).
Čas do napredovanja bolezni je bil v kraku s kombinacijo docetaksel + kapecitabin boljši (p < 0,0001).
29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p<0.0001).
Čas do napredovanja bolezni je bil v kraku s kombinacijo docetaksel + kapecitabin boljši (p < 0,0001).
290
DOE
290 micrograms/day in 18 healthy volunteers, approximately 3 to 5% of the dose was recovered in the faeces, virtually all of it as the des-tyrosine active metabolite.
290 mikrogramov/dan 18 zdravim prostovoljcem so v blatu zaznali približno 3 do 5 % odmerka, skoraj v celoti v obliki aktivnega presnovka des-tirozina.
294 (3x98) tablets (multipack)
294 (3x98) tablet (skupno pakiranje)
294 tablets
294 tablet
294 tablets: fourteen transparent calendar blisters of 21 tablets each.
294 tablet: štirinajst prozornih, z dnevi označenimi pretisnimi omoti po 21 tablet.
2947 (2612; 3326)
Študija MenACW
297 tablets
297 tablet
2970 Hørsholm Denmark or
2970 Hørsholm Danska ali
2970 ± 852 ng/ml for tegafur, 1483 ± 527 ng.hr/ml and 305 ± 116 ng/ml for gimeracil, and
2970 ± 852 ng/ml za tegafur, 1483 ± 527 ng.hr/ml in 305 ± 116 ng/ml za gimeracil ter
2: adverse reactions noted with increased frequency when bexarotene was administered at a dose of 300 mg/m2/day in non-CTCL cancer patients.
2: neželene reakcije so bile opažene z višjo pogostostjo, če je bil beksaroten uporabljen v odmerku 300 mg/m2/dan pri bolnikih brez CTCL
2: For further description, please see sub-section “Description of selected adverse reactions”
2: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«.
2: For further description, please see sub-section “Description of selected adverse reactions” Additional information on individual components
2: Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov« Dodatni podatki o posameznih sestavinah zdravila
2: Plunger head
2: glava bata
2a Snap open Blue port.
2a Odlomite (odprite) modri priključek.
2adjuvanted by AS04 containing:
2z adjuvansom AS04, ki vsebuje:
2adsorbed on AlPO4 0.2 milligrams Al3+
2adsorbiran na AlPO4 0,2 miligramov Al3+
2adsorbed on aluminium hydroxide (0.5 mg Al3+)
2 adsorbirano na aluminijev hidroksid (0,5 mg Al3+)
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
2 adsorbiran na hidratirani aluminijev hidroksid (Al(OH)3) 0,5 miligrama Al3+ v celoti
2Adsorbed on aluminium hydroxide, hydrated 0.025 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.2 milligrams Al3+
2Adsorbiran na hidratirani aluminijev hidroksid 0,025 miligrama Al3+ 3Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae) 4Adsorbiran na aluminijev fosfat 0,2 miligrama Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al3+
2Adsorbiran na hidratirani aluminijev hidroksid 0,05 miligrama Al3+ 3Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae) 4Adsorbiran na aluminijev fosfat 0,4 miligrama Al3+
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorbiran na aluminijev fosfat (skupno 0,5 miligramov Al3+)
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorbiran na aluminijev fosfat (skupno 0.5 milligramov Al3+ )
2Adverse reaction occurred both during the treatment phase and on the day of screening
1Neželeni učinek med fazo zdravljenja in na dan presejanja.
2Adverse reaction occurred both during the treatment phase and on the day of screening
2Neželeni učinek med fazo zdravljenja in na dan presejanja.
2Based on a logistic regression.
2Na podlagi logistične regresije.
2c Withdraw exactly 19 mL of the solution and unscrew the syringe.
2c Odvzemite natančno 19 ml raztopine in brizgo odvijte.
2CFU – colony forming units
2 k.e. – kolonijske enote
2D barcode carrying the unique identifier code
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
2D barcode carrying the unique identifier included
Vsebuje dvodimenzionalno črtno kodo z edinstevno oznako.
2D barcode carrying the unique identifier included.
Vsebuje dvodimenzionalno črtno kodo z enoličnim identifikatorjem.
2D barcode carrying the unique identifier included. [outer packaging only]
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako. [samo na zunanji ovojnini]
2Estimated median survival
2 ocenjeni srednji čas preživetja
2Estimated median survival
2 ocenjeno mediano preživetje
2Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4).
2 Pri bolnikih, ki so se zdravili s topotekanom, so poročali o smrti zaradi sepse (glejte poglavje 4.4).
2H2N(13CO)NH2 + 2H2O Enzyme urease 4NH3 + 213CO2
2H2N(13CO)NH2 + 2H2O encim ureaza 4NH3 + 2 13CO2
2H2N(13CO)NH2 + 2H2O Enzyme urease 4NH3 + 213CO2
2H2N(13CO)NH2 + 2H2O encim ureaza 4NH3 + 213CO2
2nd appearance
2. pojav
2nd dose
odmerek
2nd dose 20 micrograms on day 3
odmerek 20 mikrogramov na dan 3
2nd dose level reduction
Drugo zmanjšanje ravni odmerka
2nd dose reduction
drugo znižanje odmerka
2nd infusion
2. infuzija
2nd injection: 3 weeks after 1st injection.
injekcija: od 3 meseca starosti. injekcija: 3 tedne po prvem cepljenju
2nd injection: after 3 weeks
injekcija: od 2,5 meseca starosti. injekcija: po 3 tednih
2nd injection: after 3 weeks.
injekcija: od 3 meseca starosti. injekcija: po 3 tednih
2nd injection: after 3 weeks.
injekcija: od 3 mesecev starosti. injekcija: po 3 tednih.
2nd injection: after 3-4 weeks
Drugi odmerek: po 3-4 tednih
2nd injection: after 3-4 weeks.
Drugi odmerek: po 3-4 tednih
2nd injection: after 3–4 weeks.
Drugi odmerek: po 3-4 tednih.
2nd injection: after 3–4 weeks.
Drugi odmerek: po 3–4 tednih.
2nd occurrence
Pojav
2nd occurrence: 20 mg
2. pojav: 20 mg
2nd scheme - vaccination against equine influenza and tetanus:
Shema 2 – cepljenje proti influenci konj in tetanusu:
2nd scheme – vaccination against equine influenza and tetanus:
Shema 2 – cepljenje proti influenci konj in tetanusu:
2nd treatment
druga infuzija
2nd Trimester n = 17*
2. trimesečje n = 17
2nd year
2. leto
2Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan- induced neutropenia (see section 4.4).
2Kot zaplet nevtropenije, nastale zaradi topotekana, so bili opisani primeri nevtropeničnega kolitisa, tudi s smrtnim izidom (glejte poglavje 4.4).
2Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4).
2Kot zaplet nevtropenije, nastale zaradi topotekana, so bili opisani primeri nevtropeničnega kolitisa, tudi s smrtnim izidom (glejte poglavje 4.4).
2Only in the initial combination therapy.
2Samo med uvodno kombiniranim zdravljenjem.
2p-value for PFS/OS based on stratified log-rank test; p-value for Objective Response Rate based on logistic regression
2 vrednost p za PFS/OS na osnovi stratificiranega testa log-rank; vrednost p za stopnjo objektivnega odziva na osnovi logistične regresije
2Patients requiring the administration of  3 units of packed red blood cells per day for 2 consecutive days without an identified site of bleeding
2Bolniki, ki so potrebovali dajanje  3 enot koncentriranih eritrocitov na dan 2 zaporedna dneva brez ugotovljenega mesta krvavitve.
2PFU = Plaque-forming units
2PFU (Plaque-forming units) = enote, ki tvorijo plak
2RD=F: Rebound or discontinuation equal failure analysis which is equivalent to TLOVR.
2RD = F: Analiza "povraten učinek ali prenehanje, kar je enako neuspehu" in je enakovredno TLOVR.
2Reported in patients with narcolepsy and as a temporary event following vaccination
2 Opisano pri bolnikih z narkolepsijo in kot prehoden učinek po cepljenju.
2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of 1:40, or who were seropositive at pre-vaccination and have a 4- fold increase in titre;
2Delež serokonverzije: delež preiskovancev, ki so bili pred cepljenjem seronegativni in imajo po cepljenju zaščitni titer  1:40, ali so bili pred cepljenjem seropozitivni in imajo 4-kraten porast titra.
2Vaccine efficacy
2Učinkovitost cepiva
2Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.
2 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenju z drugimi hipoglikemiki.
2x carton for blister pack containing 150 mg maraviroc film-coated tablets
2× škatla za pretisne omote s 150 mg filmsko obloženii tabletami
2x carton for blister pack containing 300 mg maraviroc film-coated tablets
2× škatla za pretisne omote s 300 mg filmsko obloženii tabletami
3 % CO2 breath concentration
Dovod vzorca
3 % of subjects reaching a serum neutralising antibody titre of at least 1:80
3 % preiskovancev, ki so dosegli serumski titer nevtralizirajočih protiteles vsaj 1:80
3 (0.8)
Motnje ravnotežja
3 (1.7)
Motorične motnje
3 (3 x 1) pre-filled pens (multipack)
3 (3 x 1) napolnjeni injekcijski peresniki (večkratno pakiranje)
3 (3 x 1) pre-filled syringes (multipack)
3 (3 x 1) napolnjene injekcijske brizge (večkratno pakiranje)
3 (3 x 1) vials (multipack)
3 (3 x 1) viale (multiplo pakiranje)
3 (3 X1) vials + 3 (3 X1) syringes (multipack)
3 (3 x 1) viale +
3 (3x1) pre-filled pens
3 (3x1) napolnjeni peresniki
3 (3x1) pre-filled syringe (multipack)
3 (3 x 1) napolnjena brizga (skupno pakiranje)
3 (3x1) pre-filled syringes
3 (3x1) napolnjene brizge
3 (conditional)
3 (pogojno)
3 - 6 years old
3 –6 let
3 - 8 years
3 - 8 let
3 - < 5 years
Otroci 3 - < 5 let
3 1500 mg; Study DUR001-303 subjects with evaluable PK sample.
1500 mg; študija DUR001-303 oseb z ovrednotenim PK vzorcem.
3 3.7% of the overall randomised patient population had Stage IIIB disease.
3 3,7 % celotne populacije randomiziranih bolnic je imelo bolezen stadija III B.
3 5.8% of the overall randomised patient population had Stage IIIB disease.
3 5,8 % celotne populacije randomiziranih bolnic je imelo bolezen stadija III B.
3 89143 Blaubeuren Germany
3 89143 Blaubeuren Nemčija
3 95% CI
3 95-odstotni IZ
3 95% CI for one sample binomial using Pearson-Clopper method
3 95-% interval zaupanja (IZ) za binomski test enega vzorca z uporabo Pearson-Clopperjeve metode.
3 [1 pre-filled
3 [1 napolnjena injekcijska brizga
3 additional adverse reaction observed with brimonidine monotherapy
3 dodatni neželeni učinek, ki so ga opazili pri monoterapiji z brimonidinom
3 additional adverse reactions observed with brinzolamide monotherapy
3 dodatni neželeni učinki, ki so jih opazili pri monoterapiji z brinzolamidom
3 additional bar code labels
tri dodatne etikete s črtnimi kodami.
3 Adverse reaction identified for tenofovir disoproxil fumarate.
3 Neželeni učinek, ki so ga zabeležili za dizoproksiltenofovirijev fumarat.
3 Adverse reactions identified from emtricitabine+tenofovir alafenamide clinical studies.
3 Neželeni učinki, ki so jih zabeležili v kliničnih študijah emtricitabina + alafenamidtenofovirata.
3 Adverse reactions reported in the SmPC of at least one of the individual components, but reported with Brimica Genuair 340/12 micrograms at an incidence lower than or comparable to that of placebo.
3 Neželeni učinki, omenjeni v Povzetku glavnih značilnosti zdravila vsaj ene posamezne učinkovine, vendar je bila njihova pogostnost pri zdravilu Brimica Genuair 340/12 mikrogramov nižja od placeba ali primerljiva z njim.
3 Adverse reactions reported in the SmPC of at least one of the individual components, but reported with Duaklir Genuair 340/12 micrograms at an incidence lower than or comparable to that of placebo.
3 Neželeni učinki, omenjeni v Povzetku glavnih značilnosti zdravila vsaj ene posamezne učinkovine, vendar je bila njihova pogostnost pri zdravilu Duaklir Genuair 340/12 mikrogramov nižja od placeba ali primerljiva z njim.
3 after a PR, 1 patient that was considered a treatment failure by the IRRP and 1 that was considered not evaluable by the IRRP).
1 bolnika je bilo ocenjeno kot neuspelo po IRRP, zdravljenje enega po so pri IRRP označili kot zdravljenje, ki ga ni mogoče oceniti).
3 alcohol wipes
3 alkoholne zložence
3 Antigen Units
3 antigenskih enot
3 applicators
3 aplikatorji
3 As a consequence of local oedema
3 kot posledica lokalnega edema
3 avenue George V FR-75008 Paris France
3 avenue George V FR-75008 Pariz Francija
3 Based on a Cox’s regression model.
3 Na podlagi Coxovega regresijskega modela.
3 Based on patients with response only; DoR defined as the time from the date of first documented response (confirmed complete response or partial response, or stable disease ≥6 weeks).
3 Samo na podlagi bolnikov z odzivom; trajanje odziva opredeljeno kot čas od datuma prvega dokumentiranega odziva (potrjen popolni odziv ali delni odziv ali stabilna bolezen ≥ 6 tednov).
3 Betaferon vials (with powder for solution for injection)
3 viale zdravila Betaferon (s praškom za raztopino za injiciranje),
3 blisters (30 oral lyophilisates)
3 Pretisni omot (30 Oralni liofilizat)
3 blisters are packed together in an aluminium foil wrapper containing a desiccant.
3 pretisni omoti so pakirani v ovitku iz aluminijaste folije s sušilnim sredstvom.
3 blisters are packed together within a protective aluminium foil wrapper, including a desiccant.
3 pretisni omoti so pakirani skupaj v ovitku iz aluminijaste folije s sušilnim sredstvom.
3 blisters of
3 pretisni omoti z
3 bottles
+ 3 steklenicah
3 bottles
vsebniki
3 bottles of 180 tablets with outer carton
3 steklenice s po 180 tabletami z zunanjo ovojnino
3 bottles of 360 tablets with outer carton
3 steklenice s po 360 tabletami z zunanjo ovojnino
3 bottles of 500 ml diluent
3 steklenice s 500 ml vehikla.
3 cartridges
3 peresniki
3 cartridges
6 vložkov
3 cartridges
EU/1/97/030/066
3 cartridges
ubkutana uporaba
3 cartridges of 3 ml
3 vložki s 3 ml
3 cartridges of 3 ml.
vložki s 3 ml.